June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Distribution of optical coherence tomographic morphologic components within areas appearing as atrophic or scarred after two years of anti-VEGF treatment for neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials
Author Affiliations & Notes
  • Cynthia A Toth
    Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
  • Vincent Tai
    Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
  • Maxwell Pistilli
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Stephanie Chiu
    Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
  • Katrina Winter
    Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
  • Ebenezer Daniel
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Juan E Grunwald
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Glenn J Jaffe
    Ophthalmology, Duke University Eye Center, Durham, North Carolina, United States
  • Daniel F Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Gui-Shuang Ying
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Sina Farsiu
    Biomedical Engineering, Duke University , Durham, North Carolina, United States
  • Maureen G Maguire
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Cynthia Toth, Alcon Laboratories (P), Genentech (F); Vincent Tai, None; Maxwell Pistilli, None; Stephanie Chiu, Patent number 8,811,745 for "Segmentation and identification of layered structures in images" (P); Katrina Winter, None; Ebenezer Daniel, None; Juan Grunwald, None; Glenn Jaffe, Heidelberg Engineering (C); Daniel Martin, None; Gui-Shuang Ying, Chengdu Kanghong Biotech Co (C), Janssen Research & Development LLC (C); Sina Farsiu, None; Maureen Maguire, Genentech (C)
  • Footnotes
    Support  Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828, and R21EY023689 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1195. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Cynthia A Toth, Vincent Tai, Maxwell Pistilli, Stephanie Chiu, Katrina Winter, Ebenezer Daniel, Juan E Grunwald, Glenn J Jaffe, Daniel F Martin, Gui-Shuang Ying, Sina Farsiu, Maureen G Maguire; Distribution of optical coherence tomographic morphologic components within areas appearing as atrophic or scarred after two years of anti-VEGF treatment for neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1195.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Geographic atrophy (GA) and scar are more prevalent at two years in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) than at baseline and are associated with poorer visual acuity. We sought to identify the distribution of optical coherence tomography (OCT)-based retinal and subretinal components across sites of macular scar or atrophy, as determined by color photography and fluorescein angiography (CP/FA) after two years of treatment in the CATT.

Methods : Imaging sessions for 70 eyes at year 2 in CATT were selected from original CP and FA grading, selecting eyes with GA (present in 25 eyes), non-GA (44 eyes), fibrotic scar (FS, 26 eyes) or non-FS (7 eyes) as at least one macular component delineated at year 2 by CP/FA readers. Two eyes were excluded for poor image quality. OCT readers (masked to CP/FA) delineated OCT retinal and subretinal morphologic characteristics. Using custom software and graphic user interfaces data were registered so that presence of each OCT and CP/FA feature, and subretinal lesion thickness at each assigned en face pixel could be determined (Figure).

Results : Of all pixels designated as GA by CP/FA, 79.4% had increased choroidal signal on OCT (versus 31.5% for NGA, 39.8% FS, 15.1% non-FS, and 4.6% non-lesion, respectively), 82.3% had localized photoreceptor layer thinning (versus 39.5% for NGA, 47.7% FS, 20.7% non-FS and 10.6% non-lesion, respectively), and 30.6% had subretinal lesion components present (versus 46.8% for non-GA, 90.2% FS, 74.0% non-FS, and 4.4% non-lesion respectively). Mean (± standard deviation) thickness (microns) of subretinal material + RPE was 48 (± 25) for GA, 61 (± 35) non-GA, 151 (± 74) FS, 83 (± 17) non-FS, and 33 (± 6) non-lesion, respectively, which were significantly different (p<0.001).

Conclusions : In contrast to non-lesion areas, photoreceptor thinning and increased choroidal signal on OCT were found in both scar and atrophic areas after 2 years of anti-VEGF treatment. Subretinal lesion thicknesses and distribution of OCT components varied by presence of scar or atrophy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Images from an eye with geographic atrophy

Images from an eye with geographic atrophy

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×